User menu

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.

Bibliographic reference Jamar, François ; Barone, Raffaella ; Mathieu, Isabelle ; Walrand, Stephan ; Labar, Daniel ; et. al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.. In: European journal of nuclear medicine and molecular imaging, Vol. 30, no. 4, p. 510-8 (2003)
Permanent URL
  1. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Rev 1991; 12:450–482.
  2. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995; 36:1825–1835.
  3. Krenning EP, Kooij PP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, Oei HY, de Jong M, Visser TJ, Reijs AE, Lamberts SW. Radiotherapy with a radiolabeled somatostatin analogue [111In-DTPA-d-Phe1]-octreotide. A case history. Ann N Y Acad Sci 1994; 733:496–506.
  4. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32:110–122.
  5. McCarthy KE, Woltering EA, Espanan GD, Cronin M, Maloney TJ, Anthony LB. In situ radiotherapy with111In-pentetreotide: initial observations and future directions. Cancer J Sci Am 1998; 4:94–102.
  6. Stolz B, Smith-Jones P, Albert R, Albert R, Tolcsvai L, Briner U, Ruser G, Mäcke H, Weckbecker G, Bruns C. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion 1996; 57(Suppl 1):17–21.
  7. Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-d-Phe1, Tyr3]octreotide (90Y-SMT487) eradicates experimental rat pancreatic CA 20948 tumors. Eur J Nucl Med 1998; 25:668–674.
  8. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet 1998; 351:417–418.
  9. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq90Y-DOTATOC. J Nucl Med 2002; 43:610–616.
  10. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, Caracciolo M, Mäcke HR, Chinol M, Paganelli G. Receptor-mediated radionuclide therapy with90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med in press; DOI 10.1007/s00259-002-1023-y.
  11. Otte A, Hermann R, Heppeler A, Béhé M, Jermann E, Powell P, Maecke HR, Muller J. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26:1439–1447.
  12. de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32:133–140.
  13. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with90Y-DOTATOC. Eur J Nucl Med 2001; 28:1552–1554
  14. Akizawa H, Arano Y, Uezono T, Ono M, Fujioka Y, Uehara T, Yokoyama A, Akaji K, Kiso Y, Koizumi M, Saji H. Renal metabolism of111In-DTPA-d-Phe1-octreotide in vivo. Bioconjug Chem 1998; 9:662–670.
  15. Hammond PJ, Wade AF, Gwilliam ME, Peters AM, Myers MJ, Gilbey SG, Bloom SR, Calam J. Amino acid infusion blocks renal tubular uptake of an indium-labeled somatostatin analogue. Br J Cancer 1993; 67:1437–1439.
  16. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, Mäcke H, de Jong M.d-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997; 38:1929–1933.
  17. de Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, Krenning EP. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996; 37:1388–1392.
  18. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. EurJ Nucl Med 1998; 25:201–212.
  19. Rolleman EJ, Valkema R, de Jong M, Kooij PPM, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med 2003; 30:9–15.
  20. Rösch F, Herzog H, Stolz B, Brockmann J, Köhle M, Mühlensiepen H, Marbach P, Müller-Gärtner HW. Uptake kinetics of the somatostatin receptor ligand [86Y]-d-Phe1, Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue. Eur J Nucl Med 1999; 26:358–366.
  21. Förster GJ, Engelbach MJ, Brockmann J, Reber HJ, Buchholz HG, Mäcke HR, Rösch FR, Herzog HR, Bartenstein PR. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of86Y-DOTATOC and 111In-DTPA-octreotide. Eur J Nucl Med 2001; 28:1743–1750.
  22. Rösch F, Qaim SM, Stöcklin G. Production of the positron emitting radioisotope86Y for nuclear medical applications. Int J Appl Radiat Isot 1993; 44:677–681.
  23. Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss WD. The ECAT EXACT HR: performance of a new high-resolution positron scanner. J Comput Assist Tomogr 1994; 18:110–118.
  24. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994; 13:601–609.
  25. Walrand SH, Jamar F, Mathieu I, De Camps J, Lonneux M, Sibomana M, Labar D, Michel C, Pauwels S. Quantification in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med in press. DOI 10.1007/s00259-002-1068-y.
  26. ICRP Publication 41. Radiation protection. Nonstochastic effects of ionizing radiation. New York: Pergamon Press, 1991.
  27. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y. Interpretation of measured red cell mass and plasma volume in adults. Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89:748–756.
  28. Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, Maecke HR, Jermann E, Robertson C, Fiorenza M, Tosi G, Paganelli G. Biokinetics and dosimetry in patients administered with111In-DOTA-Tyr3-octreotide: implication for internal radiotherapy with 90Y-DOTATOC. Eur J Nucl Med 1999; 26:877–886.
  29. de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, Visser TJ, Jermann E, Béhé M, Powell P, Mäcke HR. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24:368–371.
  30. Jonard P, Jamar F, Walrand S, Labar D, Mathieu I, Smith C, Kvols L, Krenning EP, Pauwels S. Effect of peptide amount on biodistribution of86Y-DOTA-Tyr3-octreotide (SMT487). J Nucl Med 2000; 41(Suppl):260P.
  31. Mogensen CE, Sølling K. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977; 33:477–486.